🧫
Molecular characterization of RBG-NLRP3 binding interaction
active
experiment
Created: 2026-04-11T00:50:00
By: etl-v1-backfill
Quality:
50%
✓ SciDEX
ID: exp-8c4df498-6bf5-43f0-a8b5-f742a5159986
🧫 Experiment Protocol
ExploratoryatherosclerosisNLRP3purified proteins and molecular simulationproposed
This molecular study characterized the direct binding interaction between RBG and the NLRP3 protein using multiple complementary approaches. Molecular docking simulations were performed to predict binding sites, followed by surface plasmon resonance (SPR) assays to measure binding kinetics and affinity. Pull-down assays were conducted to confirm the physical interaction between RBG and NLRP3. The study identified that RBG forms a non-covalent interaction with the CYS-279 residue of NLRP3, which effectively hinders inflammasome assembly and confirms RBG's role as a potent NLRP3 inhibitor.
PRIMARY OUTCOME
binding affinity and interaction site identification
EXPECTED OUTCOMES
Expected to identify specific binding site and confirm direct interaction. Results identified a non-covalent interaction between RBG and the CYS-279 residue of NLRP3, confirming RBG as a potent NLRP3 inhibitor
SUCCESS CRITERIA
demonstration of direct binding and identification of binding site
PROTOCOL
molecular docking simulations, surface plasmon resonance (SPR) binding assays, and pull-down studies to characterize RBG-NLRP3 interaction
LINKED HYPOTHESES
Source: PMID 40258472 ↗
🧫 Experiment Extras
PATHWAY
NLRP3 inflammasome assembly
MARKET PRICE
$0.50
STATUS
proposed
▸Metadataorigin_type: v1_polymorphic_backfill
| origin_type | v1_polymorphic_backfill |
| source_table | experiments |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.